<DOC>
	<DOCNO>NCT01881568</DOCNO>
	<brief_summary>The main objective evaluate efficacy safety topical Tranexamic Acid ( TA ) reduce blood transfusion rate total knee arthroplasty . The secondary endpoint estimate visible blood loss 24 hour surgery , invisible blood loss serial counting Hb/Htc . Methodology . TRANEX1 phase III , unicentric , control , randomize , double blind clinical trial compare efficacy safety topical TA versus intravenous TA multimodal protocol , no-inferiority criterion ( n=79 ) .</brief_summary>
	<brief_title>Efficacy Comparison Topical Intravenous Tranexamic Acid Reduce Number Blood Transfusions TKA</brief_title>
	<detailed_description>The group compare ITT PP . The non-inferiority would estimate compare confidence interval use traditional test , Wilson test .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Adult patient ( great 18 year old ) Patients schedule primary unilateral knee arthroplasty Patients La Paz Cantoblanco Hospital , Madrid , Spain Patients refuse sign Inform Consent Allergy tranexamic acid Major comorbidities : Severe ischemic heart disease ( class III IV New York Heart Association ) ; sleep apnea syndrome ; severe EPOC ; renal dysfunction ( plasma creatinine &gt; 2mg/dL men &gt; 1.8mg/dL woman ) ; hepatic disfunction . Coagulopathy ( preoperative platelet count &lt; 150,000/mm3 , INR &gt; 1.4 , prolong PPT ( &gt; 1.4 x normal ) History thromboembolic disease : CVA , DVT , PE Blood dyscrasia Retinopathy ( disturbance color vision ) Jehovah 's witness Pregnancy Breastfeeding Been participate participated year ago another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Total Knee Arthroplasty , TKA , blood loss</keyword>
</DOC>